Skip to main content

LCD L35026: Rituximab

LCD L35026, Rituximab, is the Local Coverage Determination that Palmetto GBA applies to claims from 7 states (AL, GA, NC, SC, TN, VA, WV), effective 2024-11-28 and first in force 2015-10-01. The policy text runs 686 words, and its billing and coding article A56380 lists 692 ICD-10-CM codes that support medical necessity for 6 procedure codes. No other contractor publishes a policy with this title.

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: Medicare Coverage Database LCD export: MCD release November 12, 2026 (effective November 8, 2026); Medicare Coverage Database billing and coding articles: MCD release November 12, 2026 (effective November 8, 2026). Next CMS release: weekly, every Thursday.

Contractor
Palmetto GBA
States and territories
7
AL GA NC SC TN VA WV
Revision effective
2024-11-28
Original effective
2015-10-01
Policy text
686 words
Covered ICD-10 codes (articles)
692

Where this LCD applies

Each contract number is a jurisdiction on the remittance; the policy binds claims processed under these contracts and no others.

Contracts that apply LCD L35026
ContractContractorTypeStates
11201Palmetto GBAA and B and HHH MACSC
11301Palmetto GBAA and B and HHH MACVA
11401Palmetto GBAA and B and HHH MACWV
11501Palmetto GBAA and B and HHH MACNC
11202Palmetto GBAA and B and HHH MACSC
11302Palmetto GBAA and B and HHH MACVA
11402Palmetto GBAA and B and HHH MACWV
11502Palmetto GBAA and B and HHH MACNC
10111Palmetto GBAA and B MACAL
10211Palmetto GBAA and B MACGA
10311Palmetto GBAA and B MACTN
10112Palmetto GBAA and B MACAL
10212Palmetto GBAA and B MACGA
10312Palmetto GBAA and B MACTN

Billing and coding article A56380: diagnoses and procedure codes

Since 2019 the codes live in the companion article rather than the LCD. Billing and Coding A56380 (Billing and Coding: Rituximab) carries the diagnosis and procedure lists the contractor loads as the claims edit. CPT codes are shown as bare numbers because the descriptors are licensed by the AMA; HCPCS Level II descriptors are public and shown. Each article below opens its complete covered and non-covered ICD-10-CM lists, by group and with the contractor's group instructions, and the LCD code lookup answers whether one diagnosis is covered for one procedure code in a given state.

Coverage is only half of the claim edit: when two of the listed procedure codes are billed on the same date, test the pair against the NCCI edits before relying on both being paid.

A56380: Billing and Coding: Rituximab (Billing and Coding, effective 2025-10-01)

Covered ICD-10-CM codes
692
2 groups
Non-covered ICD-10-CM codes
0
Procedure codes listed
6
Full article
cms.gov record
First 24 covered ICD-10-CM codes in A56380
ICD-10-CMDescription (FY2027)
B27.00Gammaherpesviral mononucleosis without complication
C81.00Nodular lymphocyte predominant Hodgkin lymphoma, unspecified site
C81.01Nodular lymphocyte predominant Hodgkin lymphoma, lymph nodes of head, face, and neck
C81.02Nodular lymphocyte predominant Hodgkin lymphoma, intrathoracic lymph nodes
C81.03Nodular lymphocyte predominant Hodgkin lymphoma, intra-abdominal lymph nodes
C81.04Nodular lymphocyte predominant Hodgkin lymphoma, lymph nodes of axilla and upper limb
C81.05Nodular lymphocyte predominant Hodgkin lymphoma, lymph nodes of inguinal region and lower limb
C81.06Nodular lymphocyte predominant Hodgkin lymphoma, intrapelvic lymph nodes
C81.07Nodular lymphocyte predominant Hodgkin lymphoma, spleen
C81.08Nodular lymphocyte predominant Hodgkin lymphoma, lymph nodes of multiple sites
C81.09Nodular lymphocyte predominant Hodgkin lymphoma, extranodal and solid organ sites
C81.0ANodular lymphocyte predominant Hodgkin lymphoma, in remission
C81.10Nodular sclerosis Hodgkin lymphoma, unspecified site
C81.11Nodular sclerosis Hodgkin lymphoma, lymph nodes of head, face, and neck
C81.12Nodular sclerosis Hodgkin lymphoma, intrathoracic lymph nodes
C81.13Nodular sclerosis Hodgkin lymphoma, intra-abdominal lymph nodes
C81.14Nodular sclerosis Hodgkin lymphoma, lymph nodes of axilla and upper limb
C81.15Nodular sclerosis Hodgkin lymphoma, lymph nodes of inguinal region and lower limb
C81.16Nodular sclerosis Hodgkin lymphoma, intrapelvic lymph nodes
C81.17Nodular sclerosis Hodgkin lymphoma, spleen
C81.18Nodular sclerosis Hodgkin lymphoma, lymph nodes of multiple sites
C81.19Nodular sclerosis Hodgkin lymphoma, extranodal and solid organ sites
C81.1ANodular sclerosis Hodgkin lymphoma, in remission
C81.20Mixed cellularity Hodgkin lymphoma, unspecified site

Procedure codes: J3590 (Unclassified biologics), J9311 (Injection, rituximab 10 mg and hyaluronidase), J9312 (Injection, rituximab, 10 mg), Q5115 (Injection, rituximab-abbs, biosimilar, (truxima), 10 mg), Q5119 (Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg), Q5123 (Injection, rituximab-arrx, biosimilar, (riabni), 10 mg).

Coverage indications, limitations and medical necessity

Rituximab is a genetically engineered chimeric murine/human monoclonal immunoglobulin G1 (IgG1) kappa antibody directed against the CD20 antigen. Rituximab binds specifically to the antigen CD20 (human B-lymphocyte-restricted differentiation antigen, Bp35), a hydrophobic transmembrane protein with a molecular weight of approximately 35 kD located on pre-B and mature B lymphocytes. The antigen is expressed on >90% of B-cell non-Hodgkin’s lymphomas (NHL), but the antigen is not found on hematopoietic stem cells, pro-B-cells, normal plasma cells or other normal tissues.

B cells are believed to play a role in the pathogenesis of rheumatoid arthritis (RA) and associated chronic synovitis.

In non-Hodgkin’s lymphoma (NHL) patients, administration of rituximab resulted in depletion of circulating and tissue-based B cells.

In Wegener's granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) patients, peripheral blood CD19 B-cells depleted to less than 10 cells/µl following the first 2 infusions of rituximab and remained at that level in most (84%) patients through month 6. By month 12, the majority of patients (81%) showed signs of B-cell return with counts >10 cells/µL.

Food and Drug Administration (FDA) approved uses:

1. NHL

Rituximab is indicated for the treatment of patients with:

• Relapsed or refractory, low-grade or follicular, CD20-positive, B-cell NHL as a single agent.

• Previously untreated follicular, CD20-positive, B-cell NHL in combination with first line chemotherapy and, in patients achieving a complete or partial response to Rituximab in combination with chemotherapy, as single-agent maintenance therapy.

• Non-progressing (including stable disease), low-grade, CD20-positive, B-cell NHL as a single agent after first-line cyclophosphamide, vincristine and prednisone (CVP) chemotherapy.

• Previously untreated diffuse large B-cell, CD20-positive NHL in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or other anthracycline-based chemotherapy regimens.

2. Chronic lymphocytic leukemia (CLL)

Rituximab is indicated, in combination with fludarabine and cyclophosphamide (FC), for the treatment of patients with previously untreated and previously treated CD20-positive CLL.

3. RA

Rituximab in combination with methotrexate is indicated for the treatment of adult patients with moderately to severely active RA who have had an inadequate response to one or more tumor necrosis factor (TNF) antagonist therapies.

4. GPA and MPA

Rituximab in combination with glucocorticoids, is indicated for the treatment of adult patients with GPA and MPA

Accepted Off-label Uses Approved by this A/B MAC

• Second-line or salvage therapy with or without radiation therapy (RT) prior to autologous stem cell rescue for progressive disease or for relapsed disease in patients initially treated with chemotherapy with or without RT in combination with bendamustine

• Low grade or follicular CD20-positive, B-cell NHL (re-induction treatment appropriate for responders and patients with stable disease)

• Intermediate and high-grade NHL when used as a single agent, in combination with a CHOP chemotherapy regimen, or in combination with other agents active in the disease

• Immune or idiopathic thrombocytopenia purpura

• Evans’ syndrome

• Waldenstrom’s macroglobulinemia

• For the treatment of refractory thrombotic thrombocytopenic purpura (TTP) for patients who do not respond to plasmapheresis

• Autoimmune hemolytic anemia - rituximab is covered for those patients with autoimmune hemolytic anemia condition that is refractory to conventional treatment (e.g., corticosteroid treatment and splenectomy)

• Multifocal motor neuropathy (MMN) as a second line therapy

• Multiple sclerosis, relapsing, remitting (RRMS) as a third line therapy

• Neuromyelitis optica

• Polymyositis as a second or third line therapy

• Myasthenia gravis

• Anti-myelin associated glycoprotein (anti-MAG) polyneuropathy

• Graft-Versus-Host Disease (GVHD) as third line of therapy or greater

• Antineutrophil cytoplasmic antibody (ANCA) associated vasculitis

• Rituximab has been shown to be an effective therapy for cryoglobulinemia and cryoglobulinemia induced renal disease with less complications than the standard therapy with cyclophosphamide and plasmapheresis

Post-transplant lymphoproliferative disorder (PTLD)

• Epstein-Barr viremia (EBV) in patients at high risk for PTLD

allogenic bone marrow transplant patients with prolonged T-cell immune impairment

such as those receiving cord blood units or ex vivo CD34 selected or T-cell-depleted hematopoietic cell grafts, or

• patients receiving antibodies against T-cells (alemtuzumab), or

patients receiving high dose steroids for treatment of severe acute GVHD.

Autoimmune encephalitis in bone marrow transplant patients

Other off label uses will be considered for coverage at the discretion of this A/B MAC.

Summary of evidence (opening)

N/A

the full summary and analysis of evidence are in the CMS record.

Dates, lineage and related policies

Original determination effective
2015-10-01
Current revision effective
2024-11-28
Last reviewed by the contractor
2024-10-23
MCD version
75
Derived from
L34245

Using this policy on a claim

Match the documented indication to the covered indications above before the service is scheduled, carry a diagnosis from the article's covered list on the claim line (the diagnosis coverage checker tests one code pair against every article that applies in a state), and keep the elements the documentation section asks for in the record, because the contractor can request it later through medical review. A denial under this policy arrives as CARC 50 with remark N115; the LCD lookup guide walks through the appeal path and the Advance Beneficiary Notice rules, and the Palmetto GBA hub lists every other active policy from the same contractor.

For teams evaluating QuickIntell software

Where QuickIntell fits with this policy

If your team repeatedly reviews local coverage policies, explore QuickAuth for requirement checks, documentation and status tracking with staff oversight. Confirm the applicable policy, supported workflow and review responsibilities. Use QuickRCM to evaluate the separate claim and denial workflow.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions

What does LCD L35026 cover?

Rituximab is a genetically engineered chimeric murine/human monoclonal immunoglobulin G1 (IgG1) kappa antibody directed against the CD20 antigen. Rituximab binds specifically to the antigen CD20 (human B-lymphocyte-restricted differentiation antigen, Bp35), a hydrophobic transmembrane protein with a molecular weight of approximately 35 kD located on pre-B and mature B lymphocytes. The antigen is expressed on >90%… The full 686-word policy text is reproduced below from the Medicare Coverage Database export of November 12, 2026.

Which states does LCD L35026 apply to?

Palmetto GBA applies it to Medicare claims in 7 states: AL, GA, NC, SC, TN, VA, WV. It binds only that contractor; outside these jurisdictions the same service is judged under the local contractor's own policy or, where none exists, claim by claim.

Which diagnosis codes support medical necessity under LCD L35026?

The companion billing and coding article A56380 lists 692 ICD-10-CM codes in 2 groups that support medical necessity; the first 24 appear on this page, where the complete list opens by group with the contractor's group instructions.

How do I appeal a denial under LCD L35026?

A denial under LCD L35026 carries claim adjustment reason code 50 with remark code N115. Compare the documented indication with the policy's covered indications and article A56380's 692 covered diagnosis codes, then file a redetermination with Palmetto GBA within 120 days, record attached. If the service falls outside the policy, bill the patient only with a valid Advance Beneficiary Notice signed before the service.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

The policy text and code lists are reproduced from the CMS Medicare Coverage Database export as an operational reference. Verify against the current LCD and article on cms.gov before billing; coverage depends on the full record and the contractor. Not legal, clinical or billing advice.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.